Kala Pharmaceuticals Inc. (KALA) NASDAQ
$0.70 -0.04 (-5.58%)
Market Cap: $50.74M
As of 05/18/22 04:00 PM EDT. Market closed.
Kala Pharmaceuticals Inc. (KALA) NASDAQ
$0.70 -0.04 (-5.58%)
Market Cap: $50.74M
As of 05/18/22 04:00 PM EDT. Market closed.
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry ... read more
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Medicinal and Botanical Manufacturing
CEO
Mark Iwicki
Full Time Employees
188
CEO Compensation (Base)
$534,681
CEO Compensation (Total)
$3.07M
Sector
Manufacturing
Industry
Medicinal and Botanical Manufacturing
CEO
Mark Iwicki
Full Time Employees
188
CEO Compensation (Base)
$534,681
CEO Compensation (Total)
$3.07M
URL
Address
490 Arsenal Way, Suite 120, Massachusetts, Watertown, 02472.
PRICE CHART
From:
To:
KEY STATS
Open
$0
Previous Close
$0.74
Days Range
$0.65 - $0.75
52 week range
$0.59 - $6.77
Volume
0
Avg. Volume (30 days)
756,878
Market Cap
$50.74M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
72,594,005
Open
$0
Previous Close
$0.74
Days Range
$0.65 - $0.75
52 week range
$0.59 - $6.77
Volume
0
Avg. Volume (30 days)
756,878
Market Cap
$50.74M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
72,594,005
Open in:
Open in:
INSIDER TRANSACTIONS FOR KALA PHARMACEUTICALS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | Jan 04, 2022 | Sale | $1.30 | 2,850 | 3,705 | 133,208 | Jan 05, 2022, 08:00 PM |
| Brazzell Romulus K | SEE REMARKS | Jan 04, 2022 | Sale | $1.30 | 3,504 | 4,555 | 288,345 | Jan 05, 2022, 08:00 PM |
| Bazemore Todd | SEE REMARKS | Jan 04, 2022 | Sale | $1.30 | 3,454 | 4,490 | 118,591 | Jan 05, 2022, 08:00 PM |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER | Jan 04, 2022 | Sale | $1.30 | 9,518 | 12,373 | 259,158 | Jan 05, 2022, 08:00 PM |
| Trachtenberg Eric | SEE REMARKS | Jan 04, 2022 | Sale | $1.30 | 2,850 | 3,705 | 113,816 | Jan 05, 2022, 08:00 PM |
| Chen Hongming | CHIEF SCIENTIFIC OFFICER | Oct 26, 2021 | Sale | $1.80 | 9,449 | 17,008 | 225,566 | Oct 28, 2021, 08:06 PM |
| Chen Hongming | CHIEF SCIENTIFIC OFFICER | Oct 27, 2021 | Sale | $1.82 | 21,051 | 38,313 | 204,515 | Oct 28, 2021, 08:06 PM |
| Trachtenberg Eric | SEE REMARKS | Oct 26, 2021 | Sale | $1.80 | 9,449 | 17,008 | 116,666 | Oct 28, 2021, 08:05 PM |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | Oct 26, 2021 | Sale | $1.80 | 9,449 | 17,008 | 136,058 | Oct 28, 2021, 08:04 PM |
| Bazemore Todd | CHIEF OPERATING OFFICER | Oct 26, 2021 | Sale | $1.80 | 12,544 | 22,579 | 122,045 | Oct 28, 2021, 08:03 PM |
| Brazzell Romulus K | CHIEF MEDICAL OFFICER | Oct 26, 2021 | Sale | $1.80 | 12,757 | 22,963 | 291,849 | Oct 28, 2021, 08:02 PM |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER | Oct 26, 2021 | Sale | $1.80 | 27,598 | 49,676 | 268,676 | Oct 28, 2021, 08:01 PM |
| Chen Hongming | CHIEF SCIENTIFIC OFFICER | Jun 29, 2021 | Sale | $5.56 | 5,548 | 30,847 | 235,015 | Jun 30, 2021, 05:30 PM |
| Chen Hongming | CHIEF SCIENTIFIC OFFICER | Jun 28, 2021 | Sale | $5.77 | 2,452 | 14,148 | 240,563 | Jun 29, 2021, 05:26 PM |
| Brazzell Romulus K | CHIEF MEDICAL OFFICER | Jun 28, 2021 | Sale | $5.77 | 3,034 | 17,506 | 300,962 | Jun 29, 2021, 05:26 PM |
| Trachtenberg Eric | SEE REMARKS | Jun 28, 2021 | Sale | $5.77 | 2,452 | 14,148 | 126,115 | Jun 29, 2021, 05:26 PM |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | Jun 28, 2021 | Sale | $5.77 | 2,452 | 14,148 | 145,507 | Jun 29, 2021, 05:26 PM |
| Bazemore Todd | CHIEF OPERATING OFFICER | Jun 28, 2021 | Sale | $5.77 | 2,911 | 16,796 | 134,589 | Jun 29, 2021, 05:25 PM |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER | Jun 28, 2021 | Sale | $5.77 | 7,586 | 43,771 | 296,274 | Jun 29, 2021, 05:25 PM |
| Chen Hongming | Chief Scientific Officer | Mar 01, 2021 | Option Exercise | $2.30 | 9,500 | 21,850 | 243,015 | Mar 03, 2021, 12:00 AM |
| Chen Hongming | Chief Scientific Officer | Feb 25, 2021 | Option Exercise | $2.30 | 47,000 | 108,100 | 233,515 | Feb 26, 2021, 05:35 PM |
| Bazemore Todd | Chief Operating Officer | Jun 05, 2020 | Buy | $13.39 | 2 | 27 | 2 | Oct 28, 2020, 08:36 PM |
| Bazemore Todd | Chief Operating Officer | Oct 22, 2020 | Buy | $7.60 | 40 | 304 | 42 | Oct 28, 2020, 08:36 PM |
| Rosen Howard B | Director | Aug 19, 2019 | Option Exercise | $0.60 | 4,824 | 2,872 | 4,824 | Jun 29, 2020, 09:54 PM |
| Trachtenberg Eric | See Remarks | Jun 19, 2020 | Option Exercise | $5.19 | 28,901 | 149,996 | 28,901 | Jun 22, 2020, 04:06 PM |
| Reumuth Mary | Chief Financial Officer | Jun 09, 2020 | Option Exercise | $2.64 | 43,477 | 114,771 | 48,293 | Jun 11, 2020, 04:58 PM |
| Brazzell Romulus K | Chief Medical Officer | Apr 09, 2020 | Option Exercise | $2.99 | 67,771 | 202,377 | 176,496 | Apr 13, 2020, 08:38 AM |
| Chen Hongming | Chief Scientific Officer | Mar 30, 2020 | Option Exercise | $2.30 | 31,000 | 71,300 | 86,849 | Apr 01, 2020, 04:43 PM |
| Bazemore Todd | Chief Operating Officer | Mar 16, 2020 | Buy | $5.75 | 10,000 | 57,500 | 10,000 | Mar 17, 2020, 05:46 PM |
| Grunberg Gregory | Director | Mar 13, 2020 | Buy | $7.89 | 2,534,854 | 19,999,998 | 2,534,854 | Mar 16, 2020, 07:59 AM |
| Shah Rajeev M. | Director | Mar 13, 2020 | Buy | $7.89 | 6,337,135 | 49,999,994 | 10,874,613 | Mar 13, 2020, 06:47 PM |
| RA CAPITAL MANAGEMENT, L.P. | Director | Mar 13, 2020 | Buy | $7.89 | 6,337,135 | 49,999,994 | 10,874,613 | Mar 13, 2020, 06:45 PM |
| Rosen Howard B | Director | May 30, 2019 | Buy | $5.42 | 5,000 | 27,100 | 8,240 | Jun 03, 2019, 10:41 AM |
| Grunberg Gregory | Director | Oct 05, 2018 | Buy | $8.25 | 606,060 | 4,999,995 | 2,877,006 | Oct 09, 2018, 04:46 PM |
| Shah Rajeev M. | Director | Oct 03, 2018 | Buy | $8.25 | 2,424,242 | 19,999,997 | 4,537,478 | Oct 05, 2018, 04:34 PM |
| RA CAPITAL MANAGEMENT, LLC | Director | Oct 03, 2018 | Buy | $8.25 | 2,424,242 | 19,999,997 | 4,537,478 | Oct 05, 2018, 04:33 PM |
| Chen Hongming | Chief Scientific Officer | Feb 28, 2018 | Option Exercise | $2.26 | 9,769 | 22,123 | 55,849 | Mar 02, 2018, 05:19 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Feb 08, 2018 | Buy | $12.93 | 25,000 | 323,250 | 3,447,840 | Feb 12, 2018, 04:35 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Feb 02, 2018 | Buy | $14.73 | 37,840 | 557,383 | 3,422,840 | Feb 06, 2018, 05:05 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Feb 01, 2018 | Buy | $14.99 | 22,840 | 342,372 | 3,385,000 | Feb 02, 2018, 05:45 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 31, 2018 | Buy | $15.00 | 339,400 | 5,091,000 | 3,362,160 | Feb 02, 2018, 05:45 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 29, 2018 | Buy | $14.99 | 50,000 | 749,500 | 3,022,760 | Jan 30, 2018, 03:34 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 26, 2018 | Buy | $14.93 | 22,760 | 339,807 | 2,972,760 | Jan 30, 2018, 03:34 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 24, 2018 | Buy | $14.91 | 64,637 | 963,738 | 2,950,000 | Jan 24, 2018, 08:59 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 23, 2018 | Buy | $14.99 | 4,363 | 65,401 | 2,885,363 | Jan 24, 2018, 08:59 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 22, 2018 | Buy | $14.98 | 75,000 | 1,123,500 | 2,881,000 | Jan 24, 2018, 08:59 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 19, 2018 | Buy | $14.95 | 74,931 | 1,120,218 | 2,806,000 | Jan 24, 2018, 08:59 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 12, 2018 | Buy | $14.50 | 38,354 | 556,133 | 2,731,069 | Jan 24, 2018, 08:59 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 11, 2018 | Buy | $13.65 | 41,700 | 569,205 | 2,664,269 | Jan 12, 2018, 05:29 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 10, 2018 | Buy | $12.83 | 170,338 | 2,185,437 | 2,622,569 | Jan 12, 2018, 05:29 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 12, 2018 | Buy | $15.40 | 28,446 | 438,068 | 2,692,715 | Jan 12, 2018, 05:29 PM |
| Brazzell Romulus K | Chief Medical Officer | Aug 11, 2017 | Option Exercise | $1.64 | 108,725 | 178,039 | 108,725 | Aug 15, 2017, 04:08 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jul 25, 2017 | Buy | $15.00 | 319,333 | 4,789,995 | 2,375,279 | Jul 27, 2017, 07:17 PM |
| Longitude Capital Partners II, LLC | 10% Owner | Jul 25, 2017 | Buy | $15.00 | 215,000 | 3,225,000 | 2,270,946 | Jul 27, 2017, 05:23 PM |
| RA CAPITAL MANAGEMENT, LLC | Director | Jul 25, 2017 | Buy | $15.00 | 533,333 | 7,999,995 | 2,113,236 | Jul 26, 2017, 04:44 PM |
| Grunberg Gregory | Director | Jul 25, 2017 | Buy | $15.00 | 215,000 | 3,225,000 | 2,270,946 | Jul 26, 2017, 04:31 PM |
| Shah Rajeev M. | Director | Jul 25, 2017 | Buy | $15.00 | 533,333 | 7,999,995 | 2,113,236 | Jul 26, 2017, 04:31 PM |
| CDK ASSOCIATES, L.L.C. | 10% Owner | Jul 20, 2017 | Buy | $15.00 | 215,000 | 3,225,000 | 763,755 | Jul 21, 2017, 05:54 PM |
| CDK ASSOCIATES, L.L.C. | 10% Owner | Jul 20, 2017 | Buy | $15.00 | 215,000 | 3,225,000 | 763,755 | Jul 21, 2017, 03:58 PM |
| CDK ASSOCIATES, L.L.C. | 10% Owner | Jul 20, 2017 | Buy | $15.00 | 215,000 | 3,225,000 | 215,000 | Jul 20, 2017, 06:07 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | 01/04/2022 | 3,705 |
| Brazzell Romulus K | SEE REMARKS | 01/04/2022 | 4,555 |
| Bazemore Todd | SEE REMARKS | 01/04/2022 | 4,490 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER | 01/04/2022 | 12,373 |
| Trachtenberg Eric | SEE REMARKS | 01/04/2022 | 3,705 |
| Chen Hongming | CHIEF SCIENTIFIC OFFICER | 10/26/2021 | 17,008 |
| Chen Hongming | CHIEF SCIENTIFIC OFFICER | 10/27/2021 | 38,313 |
| Trachtenberg Eric | SEE REMARKS | 10/26/2021 | 17,008 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | 10/26/2021 | 17,008 |
| Bazemore Todd | CHIEF OPERATING OFFICER | 10/26/2021 | 22,579 |
| Brazzell Romulus K | CHIEF MEDICAL OFFICER | 10/26/2021 | 22,963 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER | 10/26/2021 | 49,676 |
| Chen Hongming | CHIEF SCIENTIFIC OFFICER | 06/29/2021 | 30,847 |
| Chen Hongming | CHIEF SCIENTIFIC OFFICER | 06/28/2021 | 14,148 |
| Brazzell Romulus K | CHIEF MEDICAL OFFICER | 06/28/2021 | 17,506 |
| Trachtenberg Eric | SEE REMARKS | 06/28/2021 | 14,148 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | 06/28/2021 | 14,148 |
| Bazemore Todd | CHIEF OPERATING OFFICER | 06/28/2021 | 16,796 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER | 06/28/2021 | 43,771 |
| Chen Hongming | Chief Scientific Officer | 03/01/2021 | 21,850 |
| Chen Hongming | Chief Scientific Officer | 02/25/2021 | 108,100 |
| Bazemore Todd | Chief Operating Officer | 06/05/2020 | 27 |
| Bazemore Todd | Chief Operating Officer | 10/22/2020 | 304 |
| Rosen Howard B | Director | 08/19/2019 | 2,872 |
| Trachtenberg Eric | See Remarks | 06/19/2020 | 149,996 |
| Reumuth Mary | Chief Financial Officer | 06/09/2020 | 114,771 |
| Brazzell Romulus K | Chief Medical Officer | 04/09/2020 | 202,377 |
| Chen Hongming | Chief Scientific Officer | 03/30/2020 | 71,300 |
| Bazemore Todd | Chief Operating Officer | 03/16/2020 | 57,500 |
| Grunberg Gregory | Director | 03/13/2020 | 19,999,998 |
| Shah Rajeev M. | Director | 03/13/2020 | 49,999,994 |
| RA CAPITAL MANAGEMENT, L.P. | Director | 03/13/2020 | 49,999,994 |
| Rosen Howard B | Director | 05/30/2019 | 27,100 |
| Grunberg Gregory | Director | 10/05/2018 | 4,999,995 |
| Shah Rajeev M. | Director | 10/03/2018 | 19,999,997 |
| RA CAPITAL MANAGEMENT, LLC | Director | 10/03/2018 | 19,999,997 |
| Chen Hongming | Chief Scientific Officer | 02/28/2018 | 22,123 |
| ORBIMED ADVISORS LLC | 10% Owner | 02/08/2018 | 323,250 |
| ORBIMED ADVISORS LLC | 10% Owner | 02/02/2018 | 557,383 |
| ORBIMED ADVISORS LLC | 10% Owner | 02/01/2018 | 342,372 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/31/2018 | 5,091,000 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/29/2018 | 749,500 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/26/2018 | 339,807 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/24/2018 | 963,738 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/23/2018 | 65,401 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/22/2018 | 1,123,500 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/19/2018 | 1,120,218 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/12/2018 | 556,133 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/11/2018 | 569,205 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/10/2018 | 2,185,437 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/12/2018 | 438,068 |
| Brazzell Romulus K | Chief Medical Officer | 08/11/2017 | 178,039 |
| ORBIMED ADVISORS LLC | 10% Owner | 07/25/2017 | 4,789,995 |
| Longitude Capital Partners II, LLC | 10% Owner | 07/25/2017 | 3,225,000 |
| RA CAPITAL MANAGEMENT, LLC | Director | 07/25/2017 | 7,999,995 |
| Grunberg Gregory | Director | 07/25/2017 | 3,225,000 |
| Shah Rajeev M. | Director | 07/25/2017 | 7,999,995 |
| CDK ASSOCIATES, L.L.C. | 10% Owner | 07/20/2017 | 3,225,000 |
| CDK ASSOCIATES, L.L.C. | 10% Owner | 07/20/2017 | 3,225,000 |
| CDK ASSOCIATES, L.L.C. | 10% Owner | 07/20/2017 | 3,225,000 |
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report: 12/31/2021
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
03/31/2021
5.75%
3Q
12/31/2020
24.49%
4Q
06/30/2020
35.18%
6Q